Terms ending in 2034
Every in-force patent on GlaxoSmithKline LLC's record whose computed term ends in 2034, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US D837,056 | Bottle and Cap Assembly In force · High confidence | Haleon US Holdings LLC | In force | High confidence | |
| US 10,590,135 | Substituted Bridged Urea Analogs as Sirtuin Modulators In force · High confidence | GlaxoSmithKline LLC | In force | High confidence | |
| US 10,286,037 | Methods of Producing Lyophilized Polypeptide Composition Formulations Comprising Volatile Additives In force · High confidence | GlaxoSmithKline LLC | In force | High confidence | |
| US 10,172,765 | Metered Dose Container In force · High confidence | GlaxoSmithKline Consumer Healthcare (UK) IP Limited | In force | High confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
2 of these are in force and held by GlaxoSmithKline LLC.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.